Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TD001 in PSMA-Expressing Metastatic Castration-Resistant Prostate Cancer
NCT07258407Phase 2Recruiting
- Sponsor
- TOAD Oncology
- Start
- Jan 2026
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 5
01
Overview
A Phase 2 trial of TOAD-1 in castration-resistant prostate cancer (CRPC), sponsored by TOAD Oncology. Started Jan 2026; status: recruiting.
02
Drugs
TOAD-1
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT07258407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07258407.